Previous close | 115.72 |
Open | 115.81 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1800 |
Day's range | 115.28 - 116.32 |
52-week range | 92.19 - 120.92 |
Volume | |
Avg. volume | 1,247,382 |
Market cap | 234.163B |
Beta (5Y monthly) | 0.50 |
PE ratio (TTM) | 23.65 |
EPS (TTM) | 4.89 |
Earnings date | 29 Oct 2024 |
Forward dividend & yield | 3.78 (3.27%) |
Ex-dividend date | 07 Mar 2024 |
1y target est | 117.31 |
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1Results remain consistent across secondary endpoints, including distant disease-free survival, with a trend for improved overall survival*1Safety is in line with previously reported results with generally low-grade symptomatic adverse events, reinforcing well-tolerated profile1People diagnosed with stage II or II
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.